T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (802)	4/17/1999 1:19:00 PM
From: scaram(o)uche	Read Replies (2) of 1073

David, BJ: OK, we have some cash in "dry-powder". I'll add NBIX. Please note that, for this portfolio, I don't get fancy and use the current ask for purchases..... I just go to the SI portfolio and use whatever price is given at the time. If a stock gaps, I'll go back and either edit out the purchase or enter the opening ask. New CSO? Urrrrrrggggggggghhhhhhhh...... I hate surprises. I thought that Paul Conlon had been doing a bang-up job. Not enough neuro background? This would be a "new" slot, correct? Not a replacement? Regarding the CRF 1 receptor antagonist....... here's the update from the recent 10-K...... Neurocrine and its corporate partner are developing small molecule therapeutics to block the effects of overproduction of CRF for the treatment of depression. The Company has developed several distinct chemical series of CRF receptor antagonists. Janssen selected a drug candidate in 1996 for preclinical testing and commenced Phase I clinical trials on the compound in late 1997 and completed these in 1998. In late 1998 a Phase II open label trial was initiated in patients with major depression. Results from this trial are expected to be available in second half of 1999. No assurance can be given that Janssen will successfully complete Phase II clinical testing of this candidate or that the Phase II data will support continuation of the program and additional clinical trials. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next